Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.
Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.
Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.
Rhea-AI Summary
Natera, Inc. (NTRA) has acquired certain assets from Invitae (NVTA) related to non-invasive prenatal screening and carrier screening business. The upfront payment to Invitae was $10 million, with potential milestone payments totaling $42.5 million. Invitae will transition its customers to Natera. Natera CEO, Steve Chapman, expressed commitment to providing excellent service and supporting additional patients and providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Invitae (NVTA) completes the sale of reproductive health assets to Natera (NTRA) for up to $52.5 million, aiming to focus on clinical germline genetic information and reduce operating expenses by approximately $44 million annually. Natera has hired Invitae reproductive health sales representatives and will take over customer transition for non-invasive prenatal and carrier screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to be presented at the American Society of Clinical Oncology’s 2024 Gastrointestinal Cancers Symposium. The data includes updated 24-month DFS analysis from GALAXY and first interim analysis from BESPOKE CRC. Natera and its collaborators will present 11 abstracts featuring new Signatera data across various GI indications, including two oral presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced the jury's verdict in a patent infringement lawsuit brought by Ravgen, Inc. The damages award of $57 million was significantly less than the $410 million sought by Ravgen. The jury also determined there was no willful infringement by Natera. The patent at issue has expired, and Natera plans to file an appeal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.3%
Tags
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) expects total revenues of approximately $300 million in the fourth quarter of 2023, an increase of approximately 38% compared to $217 million in the fourth quarter of 2022. Total revenues of approximately $1.07 billion in 2023, an increase of approximately 30% compared to $820 million in 2022. These results demonstrate significant growth and surpass the top end of the company's revenue guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) to participate in the 42nd Annual J.P. Morgan Healthcare Conference. Management to deliver a presentation and host a Q&A with the investment community. Live webcast available on investor.natera.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
News
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) has announced that the federal District Court has issued a preliminary injunction against NeoGenomics, barring them from making, using, selling, or promoting their RaDaR molecular residual disease (MRD) assay in the United States, with limited exceptions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) Announces Pan-Cancer Study Showing MTM/mL Dynamics More Predictive of Therapy Response than mVAF Dynamics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.25%
Tags
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) achieves key objective as the United States District Court for the District of Delaware denies CareDx’s motion for summary judgment on two Natera patents in an infringement lawsuit. The trial will commence on January 22, 2024, as Natera aims to protect its significant investments in innovation from unlawful infringement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) presents new data at the 2023 San Antonio Breast Cancer Symposium (SABCS) on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, showcasing leadership in personalizing patient care across the breast cancer continuum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
Natera Inc
Nasdaq:NTRA
NTRA Rankings
NTRA Stock Data
20.88B
130.00M
3.45%
93.67%
2.13%
Diagnostics & Research
Services-medical Laboratories
United States
AUSTIN